AIM
RGNX icon

Anchor Investment Management’s Regenxbio RGNX Stock Holding History

Anchor Investment Management’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-85
Closed -$2.83K – 821
2017
Q4 		$2.83K Hold
85
– – ﹤0.01% 751
2017
Q3 		$2.8K Buy
+85
New +$1.91K ﹤0.01% 723

Other funds holding RGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Anchor Investment Management's RGNX Position: Q1 2018 in Review

Anchor Investment Management sold out of Regenxbio (RGNX) in Q1 2018, closing a stake of 85 shares — an estimated $2.83K sold.

Anchor Investment Management first reported a position in RGNX in Q3 2017 and held it in 2 quarters. The position peaked at $2.83K in Q4 2017. 120 funds tracked by Wall St. Rank hold RGNX as of Q1 2018.

  • Anchor Investment Management reported no remaining Regenxbio position as of Q1 2018 after selling out during the quarter.
  • Anchor Investment Management sold 85 Regenxbio shares in Q1 2018, an estimated $2.83K.
  • Anchor Investment Management first reported a position in Regenxbio in Q3 2017 and held it in 2 quarters.
  • Anchor Investment Management's Regenxbio position peaked at $2.83K in Q4 2017.
  • 120 funds tracked by Wall St. Rank held Regenxbio as of Q1 2018.

Based on Anchor Investment Management's 13F filing for Q1 2018, filed 3 Jan 2024.